Brand Name
Relpax
Generic Name
Eletriptan
View Brand Information FDA approval date: July 12, 2017
Classification: Serotonin-1b and Serotonin-1d Receptor Agonist
Form: Tablet
What is Relpax (Eletriptan)?
RELPAX is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with RELPAX, reconsider the diagnosis of migraine before RELPAX is administered to treat any subsequent attacks., RELPAX is not intended for the prevention of migraine attacks., Safety and effectiveness of RELPAX have not been established for cluster headache. RELPAX is a serotonin receptor agonist indicated for the acute treatment of migraine with or without aura in adults Limitations of Use:, Use only after a clear diagnosis of migraine has been established , Not indicated for the prophylactic therapy of migraine , Not indicated for the treatment of cluster headache
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Phase 1b/2a Clinical Trial in Early Acute Spinal Cord Injury (SCI): a Single Blinded, Randomized, Proof-of-Concept Study to Determine the Safety, Tolerability and Efficacy of TZ-161
Summary: Technophage identified a promising compound, Eletriptan hydrobromide, that intends to use as a repurposed drug, for the treatment of acute spinal cord injury (SCI) in human subjects. Eletriptan hydrobromide is a well characterized molecule, that has been clinically available for over two decades for the treatment of migraines. It presents a good and manageable safety profile, including for the reg...